COVID-19 and rheumatic diseases: A mini-review.
COVID-19
infection
inflammation
musculoskeletal pain
reactive arthritis
rheumatic diseases
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
07
2022
accepted:
12
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Joint pain and arthralgia can be manifestations of COVID-19, and studies evaluating long COVID symptoms identified the persistence of these disorders. Moreover, some case reports highlighted the development of new inflammatory arthritis in patients with COVID-19, suggesting a possible relation. Viral infections and rheumatic diseases share a documented relationship; they have been associated with genetic and environmental risk factors responsible for some of them. There is crosstalk between viruses and the immune system during the development of several rheumatic diseases. Moreover, infections may participate in the pathogenesis of autoimmune rheumatic diseases and contribute to patient mortality. Therefore, it is crucial to provide a clearer insight into the interaction between viral infections and rheumatic diseases. Here, we provide a mini-review of the current literature with the aim of shedding light on the relationship between COVID-19 and rheumatic or musculoskeletal diseases, which is still unclear. Specifically, we examined several aspects: risk for the rheumatic population of acquiring the virus or developing severe symptoms, similarities of COVID-19 and arthritis, the possible rheumatic consequence of COVID-19, of rheumatic drugs and vaccines, and COVID-19 prevention in rheumatic patients through vaccination.
Identifiants
pubmed: 36226148
doi: 10.3389/fmed.2022.997876
pmc: PMC9548696
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
997876Informations de copyright
Copyright © 2022 Roseti and Grigolo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ther Clin Risk Manag. 2008 Oct;4(5):1023-33
pubmed: 19209283
Biomed Pharmacother. 2022 Jan;145:112385
pubmed: 34915673
Biomedicines. 2022 Apr 01;10(4):
pubmed: 35453585
Transl Res. 2021 Jun;232:49-59
pubmed: 33626415
J Med Virol. 2021 Dec;93(12):6458-6459
pubmed: 34297354
Med Hypotheses. 2021 Aug;153:110638
pubmed: 34217126
Clin Rheumatol. 2022 Jun;41(6):1641-1652
pubmed: 35247132
Science. 2020 Jun 26;368(6498):1422-1424
pubmed: 32461212
Arthritis Rheumatol. 2021 Feb;73(2):e1-e12
pubmed: 33277981
Clin Rheumatol. 2021 Jul;40(7):2611-2619
pubmed: 33733315
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101657
pubmed: 33468418
Adv Rheumatol. 2021 Jul 8;61(1):45
pubmed: 34238376
Front Public Health. 2020 Jul 29;8:383
pubmed: 32850602
Int J Infect Dis. 2022 Aug;121:24-30
pubmed: 35462039
Clin Rheumatol. 2021 Sep;40(9):3533-3545
pubmed: 33751280
Int J Mol Sci. 2022 Jan 10;23(2):
pubmed: 35054906
Front Med (Lausanne). 2022 Jan 27;8:808608
pubmed: 35155485
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2019 Apr 27;393(10182):1745-1759
pubmed: 31034380
Ann Rheum Dis. 2021 Apr;80(4):e58
pubmed: 32471899
Reumatol Clin. 2013 Jul-Aug;9(4):229-38
pubmed: 22944142
Clin Pharmacol Ther. 2020 Oct;108(4):719-729
pubmed: 32438454
Rheumatol Int. 2020 Oct;40(10):1539-1554
pubmed: 32666137
Aust Prescr. 2020 Oct;43(5):146-147
pubmed: 33093739
Autoimmun Rev. 2021 Apr;20(4):102792
pubmed: 33610751
Int Immunopharmacol. 2021 Dec;101(Pt B):108256
pubmed: 34673298
Ann Intern Med. 2020 Sep 1;173(5):W86
pubmed: 32687391
Nat Rev Rheumatol. 2022 Apr;18(4):191-204
pubmed: 35217850
Arthritis Rheumatol. 2020 Oct;72(10):1600-1606
pubmed: 32506699
Clin Rheumatol. 2020 Jul;39(7):2069-2075
pubmed: 32472461
Arthritis Rheumatol. 2021 Jan;73(1):36-47
pubmed: 32741139
Ann Rheum Dis. 2020 Jul;79(7):851-858
pubmed: 32503854
Arthritis Rheumatol. 2021 Oct;73(10):e60-e75
pubmed: 34346564
J Bone Joint Surg Am. 2020 Jul 15;102(14):1197-1204
pubmed: 32675661
Nat Rev Dis Primers. 2018 Feb 08;4:18001
pubmed: 29417936
Ann Rheum Dis. 2020 Aug 4;:
pubmed: 32753423
Cells. 2021 Nov 24;10(12):
pubmed: 34943795
Nat Rev Rheumatol. 2020 Aug;16(8):465-470
pubmed: 32561873
JCI Insight. 2021 Jun 18;6(13):
pubmed: 34143756
Rheumatology (Oxford). 2017 Oct 1;56(10):1662-1675
pubmed: 28122959
Front Immunol. 2022 Jul 04;13:919979
pubmed: 35860285
Ann Rheum Dis. 2006 Mar;65(3):385-90
pubmed: 16096334
Rheumatol Int. 2021 Nov;41(11):2031-2039
pubmed: 34550429
RMD Open. 2019 Sep 19;5(2):e001041
pubmed: 31673420
Cells. 2021 Oct 23;10(11):
pubmed: 34831081
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Biomolecules. 2021 Jul 06;11(7):
pubmed: 34356617
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Arthritis Rheumatol. 2022 Jan;74(1):28-32
pubmed: 34346185
Exp Mol Med. 2019 Jul 8;51(7):1-11
pubmed: 31285419
Rheumatology (Oxford). 2021 Jul 1;60(7):e232-e233
pubmed: 33471106
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Int J Rheum Dis. 2021 Nov;24(11):1440-1441
pubmed: 34585843
Signal Transduct Target Ther. 2020 Jul 25;5(1):128
pubmed: 32712629
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI180-SI188
pubmed: 35143648
Int J Rheum Dis. 2021 Sep;24(9):1218-1220
pubmed: 34363344
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Hum Vaccin Immunother. 2021 Sep 2;17(9):2954-2956
pubmed: 34033732
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
J Pediatr. 2020 Nov;226:45-54.e1
pubmed: 32768466
Arthritis Rheum. 2012 Jun;64(6):1697-707
pubmed: 22392533
J Clin Exp Hepatol. 2012 Mar;2(1):42-54
pubmed: 25755405
JAMA. 2020 Dec 8;324(22):2251-2252
pubmed: 33206133
Ann Rheum Dis. 2021 Jul;80(7):930-942
pubmed: 33504483
Rheumatol Int. 2011 Nov;31(11):1409-17
pubmed: 21800117
Front Microbiol. 2022 Feb 10;13:789882
pubmed: 35222327
JAMA. 2021 Aug 10;326(6):499-518
pubmed: 34228774
Semin Arthritis Rheum. 2022 Aug;55:152025
pubmed: 35617780